Beyond Air (XAIR) AI Stock Analysis

• Market Cap: $14.76M
• Dividend Yield: N/A
• Average Volume (3M): 6.04M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.39
• Revenue Growth: 147.74%
• EPS Growth: 73.23%
• Country: US
• Employees: 107
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -1.25
• Shares Outstanding: 7,934,767
• 10 Day Avg. Volume: 277,876
• 30 Day Avg. Volume: 6,042,452
• PEG Ratio: <0.01
• Price to Book (P/B): 1.36
• Price to Sales (P/S): 4.98
• P/FCF Ratio: -0.42
• Enterprise Value/Market Cap: 1.55
• Enterprise Value/Revenue: 3.93
• Enterprise Value/Gross Profit: -58.67
• Enterprise Value/Ebitda: -0.72
• 1Y Price Target: $6.00
• Price Target Upside: 404.20% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $1.00 ▼(-15.97% Downside)

Beyond Air's overall stock score is primarily impacted by its weak financial performance, characterized by significant losses and high leverage. Technical indicators also suggest bearish momentum. While the earnings call provided some positive insights into revenue growth and strategic initiatives, these are not enough to offset the financial and technical challenges.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and increasing demand for Beyond Air's products, supporting long-term business expansion.

Global Expansion

Expanding global footprint enhances market reach and diversifies revenue streams, positioning Beyond Air for sustained growth across multiple regions.

Operational Improvements

Significant reduction in operating expenses improves cost efficiency, which can enhance profitability and support long-term financial health.

Negative Factors

High Leverage

Significant leverage increases financial risk and limits flexibility, potentially impacting Beyond Air's ability to invest in growth opportunities.

Leadership Transition

Leadership changes can disrupt strategic continuity and execution, potentially affecting Beyond Air's operational stability and long-term growth plans.

Negative Cash Flow Trends

Persistent negative cash flow trends indicate challenges in generating sufficient cash to support operations, which may hinder future growth and investment.

Beyond Air Business Overview & Revenue Model

Company Description

Beyond Air (XAIR) is a clinical-stage medical device and biopharmaceutical company focused on developing innovative inhaled nitric oxide therapies for various respiratory diseases. The company operates primarily in the healthcare sector, leveraging its proprietary technology to create solutions that improve patient outcomes in conditions such as pulmonary hypertension and other respiratory disorders. Beyond Air's core product is the LungFit platform, a device that delivers inhaled nitric oxide in a cost-effective and portable manner, aiming to address unmet medical needs in both hospital and home settings.

How the Company Makes Money

Beyond Air generates revenue through the commercialization of its LungFit product line, which is designed to deliver inhaled nitric oxide for therapeutic use. The company monetizes its offerings through direct sales to healthcare providers and institutions, as well as potential licensing agreements for its technology. Key revenue streams include sales from the LungFit system and associated disposables, as well as partnerships with pharmaceutical companies for collaborative development efforts. Additionally, Beyond Air may benefit from reimbursement arrangements with insurance providers, which can enhance the accessibility of its products in the market.

Beyond Air Financial Statement Overview

Summary

Beyond Air faces significant financial challenges, including substantial losses, high leverage, and negative cash flow trends. Despite some revenue growth, the company's profitability, leverage, and cash flow management remain major concerns.

Income Statement

Beyond Air's income statement reflects significant challenges in profitability. The TTM data shows a negative gross profit margin of -24.57% and a net profit margin of -880.70%, indicating substantial losses relative to revenue. While there is a positive revenue growth rate of 21.33% in the TTM, the EBIT and EBITDA margins remain deeply negative, suggesting ongoing operational inefficiencies. The company has shown some revenue growth, but profitability remains a major concern.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 1.18 in the TTM, indicating significant leverage. The return on equity is negative at -243.16%, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio is not explicitly calculated, but the high leverage and negative ROE suggest financial instability. The company needs to address its leverage and improve its equity position to enhance financial stability.

Cash Flow

Cash flow analysis shows a concerning trend with negative free cash flow growth of -27.31% in the TTM. The operating cash flow to net income ratio is -7.04, indicating that the company is not generating sufficient operating cash flow relative to its net losses. The free cash flow to net income ratio is slightly positive at 1.10, but overall cash flow management remains a significant challenge. The company needs to improve its cash flow generation to support its operations and growth.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	5.80M	3.71M	1.16M	0.00	0.00	873.00K
Gross Profit	-389.00K	-1.66M	-1.31M	-555.00K	0.00	873.00K
EBITDA	-31.87M	-41.89M	-59.03M	-58.20M	-42.70M	-22.02M
Net Income	-36.70M	-46.63M	-60.24M	-55.82M	-43.18M	-22.88M
Balance Sheet
Total Assets	30.96M	30.06M	56.96M	68.75M	99.20M	40.52M
Cash, Cash Equivalents and Short-Term Investments	10.70M	6.92M	34.47M	45.88M	80.24M	34.63M
Total Debt	11.80M	11.69M	17.84M	3.59M	3.49M	6.93M
Total Liabilities	17.87M	15.72M	29.77M	26.72M	20.99M	10.06M
Stockholders Equity	12.73M	13.58M	25.05M	37.91M	72.70M	30.46M
Cash Flow
Free Cash Flow	-26.15M	-44.10M	-61.76M	-36.89M	-24.51M	-20.53M
Operating Cash Flow	-23.67M	-38.22M	-56.02M	-33.01M	-23.13M	-19.64M
Investing Cash Flow	-3.54M	14.90M	-12.23M	-20.59M	-1.45M	-890.00K
Financing Cash Flow	8.27M	16.65M	43.17M	2.70M	79.45M	30.33M

Beyond Air Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XAIR, the sentiment is Negative. The current price of 1.19 is below the 20-day moving average (MA) of 1.45, below the 50-day MA of 1.99, and below the 200-day MA of 3.44, indicating a bearish trend. The MACD of -0.23 indicates Negative momentum. The RSI at 26.26 is Positive, neither overbought nor oversold. The STOCH value of 24.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XAIR.

Beyond Air Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TLSI	54 Neutral	$349.75M	―	―	―	49.52%	19.34%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HYPR	48 Neutral	$96.28M	-1.97	-94.03%	―	-20.10%	7.87%
LUNG	44 Neutral	$70.08M	-1.20	-73.73%	―	15.59%	4.13%
XAIR	42 Neutral	$14.76M	-0.16	-179.63%	―	147.74%	73.23%
COCH	42 Neutral	$23.32M	―	―	―	-25.18%	-9.71%
IINN	35 Underperform	$32.95M	-2.50	―	―	―	―

Beyond Air Corporate Events

Beyond Air’s Earnings Call Highlights Growth and Challenges

The recent earnings call for Beyond Air painted a picture of robust growth and strategic expansion, tempered by some challenges. The company reported strong revenue growth and global expansion, indicating a positive trajectory. However, these achievements were somewhat overshadowed by leadership transitions and flat sequential revenue growth, which may pose short-term hurdles.

Beyond Air Reports Strong Revenue Growth and Strategic Updates

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company specializing in the use of nitric oxide for treating respiratory illnesses, neurological disorders, and solid tumors. The company is known for its innovative LungFit system, which generates nitric oxide from ambient air for medical use.

Beyond Air Secures $32 Million Financing Agreement

On November 4, 2025, Beyond Air, Inc. entered into financing agreements with Streeterville Capital, securing up to $32 million in potential proceeds. This includes a $12 million promissory note and a $20 million equity line of credit. The financing aims to accelerate the company’s commercial expansion, particularly for its LungFit PH product, and potentially achieve profitability. The agreements provide flexibility for Beyond Air to enhance its operations and strategic initiatives, extending its cash runway into 2027.

The most recent analyst rating on (XAIR) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.

Beyond Air Announces New Warrant Agreement

On September 8, 2025, Beyond Air announced an agreement with holders of existing warrants to purchase 1,439,126 shares at a reduced price, generating approximately $3.18 million in gross proceeds. In return, the company will issue new unregistered warrants for 719,561 shares. The proceeds will support clinical and pre-clinical programs, with the transaction closing expected on September 9, 2025.

The most recent analyst rating on (XAIR) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.

Beyond Air’s NeuroNOS Gains FDA Orphan Drug Status

On September 8, 2025, Beyond Air‘s subsidiary, NeuroNOS, received Orphan Drug Designation from the FDA for its investigational therapy, BA-101, aimed at treating Glioblastoma, a highly aggressive brain cancer. This designation highlights the company’s commitment to addressing rare neurological conditions and marks its entry into oncology, offering potential market exclusivity and incentives for further development.

The most recent analyst rating on (XAIR) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.